Navigation Links
Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting

SAN DIEGO, May 14, 2007 /PRNewswire-FirstCall/ -- Shire plc , the market leader in treatments for Attention-Deficit/Hyperactivity Disorder (ADHD), announced that it will present key scientific data on its ADHD treatment portfolio at the American Psychiatric Association (APA) annual meeting to be held May 19 to 24 in San Diego.

"The upcoming clinical research to be presented at APA reaffirms Shire's commitment to understanding the science of ADHD treatment," said Eliseo Salinas, Chief Scientific Officer and Executive Vice President, Global R&D. "We are looking forward to sharing new scientific data from clinical trials involving our ADHD portfolio of treatments with the medical community."

Shire's portfolio of ADHD treatments includes VYVANSE(TM) (lisdexamfetamine dimesylate), the first prodrug stimulant, which is planned to launch 2Q 2007, DAYTRANA(TM) (methylphenidate transdermal system), the first and only ADHD patch, and ADDERALL XR(R) (mixed salts of a single-entity amphetamine product), a long-acting formulated stimulant. Additional ADHD treatments under development by Shire include SPD465 (triple-bead mixed amphetamine salts) and SPD503 (guanfacine HCl extended release).

A summary of the key scientific presentations is provided below. Information about the data presentations mentioned in this release is embargoed until the respective presentation sessions have taken place at the APA annual meeting.

    VYVANSE (lisdexamfetamine dimesylate):


    May 23, 2007; 3:00 p.m. PDT (6:00 p.m. EDT)

    Long-Term Effectiveness and Safety of Lisdexamfetamine Dimesylate (LDX) in

    Children Aged 6 to 12 Years With Attention-Deficit/Hyperactivity Disorder

    APA Poster# NR739


    May 23, 2007; 3:00 p.m. PDT (6:00 p.m. EDT)

    Improved Interpatient Pharmacokinetic Variability of Lisdexamfetamine

    Dimesylate Compared With Mixed Amphetamine Salts Extended Release (MAS XR)


'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Strategy for ... ... SGMO ) announced today the publication of data,demonstrating that human immune ... treatment with zinc finger DNA-binding,protein nucleases (ZFN(TM)). The data suggest that ...
... mention ongoing FDA-approved HIFU clinical trials in the, ... and experience, CHARLOTTE, N.C., June 27 USHIFU, ... for prostate cancer,treatment in North and South America, announced ... featured a segment on high intensity focused,ultrasound (HIFU) for ...
Cached Medicine Technology:Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 2Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 3Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 4Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 5Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 6ABC News NIGHTLINE Features HIFU with Sonablate(R) 500 as Non Invasive Treatment Option for Prostate Cancer 2ABC News NIGHTLINE Features HIFU with Sonablate(R) 500 as Non Invasive Treatment Option for Prostate Cancer 3
(Date:4/18/2014)... -- A group of scientists from the University ... Center on Aging has found interesting new information ... in Parkinson,s disease (PD). , Published in ... which assessed cognitive function in depressed and non-depressed ... therapy commonly used to treat motor symptoms of ...
(Date:4/18/2014)... your worst memories? How did it make you feel? ... negative personal experience, such as how sad you were ... distress, especially when you can,t stop thinking about it. ... about the context of the memories, rather than how ... to alleviate the negative effects of these memories, a ...
(Date:4/18/2014)... Medicine scientists could lead to potential new treatments for ... scleroderma. , Fibrosis, or scarring, is a hallmark ... and lungs can lead to serious organ damage and, ... therapeutic options centers on findings made by Swati Bhattacharyya, ... role that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... CHAMPAIGN, Ill. One of the most popular vaccine ... choice. And doctors may be overlooking some cost factors ... actually a more expensive option, according to a new ... of vaccines to administer can be driven by numerous ... study and a professor of computer science and of ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
... year’s polio outbreak on the wane and excellent coverage ... Group today advised// the government that the next few ... most vulnerable children, who are not being sufficiently immunized ... and international experts who advised the government on strategies ...
... Delhi: Reliance Life Sciences, the biotechnology venture of Mukesh Ambani's ... and building// a world class manufacturing unit to produce them. ... unit due to the response to its Factor VII product, ... of Factor VII in their blood that leads to serious ...
... which happens as people catch up with age is fine, but ... have major repercussions on health, increasing the chances of early death. ... 3 centimeters or more in height of men as they age ... men who lose less than a centimeter. This risk was thought ...
... study involving more than 413,000 persons from 10 countries has ... activity or two hours// of moderate activity can cut the ... 35 per cent. ,Christine Friedenreich of the International Agency ... Cancer Board carried out the study to assess how ...
... from University of Sydney suggested that having an epidural ... breastfeeding//. The study results were published in the December ... who studied 1,300 women who gave birth between March ... anaesthetic are more likely to have problems in the ...
... India, has come up with another project. This scheme named ... to cost Rs 342.81-crores. ,The Global Fund aids ... will also be spent for reducing the transmission of HIV ... including antiretroviral therapy to those already infected. ,There ...
Cached Medicine News:Health News:Polio Outbreak on Wane: Next Rounds Must Focus on Youngest Children 2
Skin Tone External Eyelid Weights...
To prevent retraction of the conjunctival cul-de-sacs without touching the cornea....
Zone Quick is a simple and accurate system that measures tear volume in just 15 seconds per eye. Each box has an easy to read diagnostic indicator rule....
... Stent has been introduced by FCI Ophthalmics, Inc. ... Lacrimal Stent addressed the limitations previously encountered with ... DCR. Brought in to position through the nose, ... is no need to pass the very large ...
Medicine Products: